iTeos Therapeutics Overview
- Founded
-
2011
- Status
-
Public
- Employees
-
125
- Stock Symbol
-
ITOS
- Share Price
-
$13.59
- (As of Friday Closing)
iTeos Therapeutics General Information
Description
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.
Contact Information
Website
www.iteostherapeutics.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Stock Exchange
NAS
Primary Office
- Rue des Frères Wright 29
- 6041 Gosselies
- Belgium
iTeos Therapeutics Timeline
iTeos Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.59 | $13.19 | $12.52 - $35.64 | $471M | 35.7M | 280K | $2.72 |
iTeos Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | (52,962) | (52,962) | 745,454 | 845,233 |
| Revenue | 267,630 | 267,630 | 344,775 | 0 |
| EBITDA | 138,178 | 138,178 | 257,067 | (37,555) |
| Net Income | 96,652 | 96,652 | 214,521 | (38,033) |
| Total Assets | 754,991 | 754,991 | 884,712 | 344,558 |
| Total Debt | 4,673 | 4,673 | 5,341 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
iTeos Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
iTeos Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
iTeos Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therap
Drug Discovery
Gosselies, Belgium
125
As of 2022
00000
0000
0000-00-00
00000000
00000
000000
m dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proiden
0000000000000
Newtown, PA
00
As of 0000
00000
00000000
00000
000000
qua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
0000000000000
Newark, CA
00
As of 0000
00000
00000000
00000
Add Comparison
iTeos Therapeutics Competitors (51)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Onconova Therapeutics | Formerly VC-backed | Newtown, PA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Newark, CA | 00 | 00000 | 00000000 | 00000 |
| 0000000 | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 00000000 | 00000 |
| 0000000 0000000000 | Corporation | Framingham, MA | 0 | 000.00 | 000000000 | 000.00 |
| 0000 00000000 | Formerly VC-backed | Boston, MA | 000 | 00000 | 000000&0 | 00000 |
iTeos Therapeutics Patents
iTeos Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2017214409-A | Pyrrolidine-2, 5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors | Pending | 15-May-2014 | ||
| CA-2942761-A1 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Inactive | 18-Mar-2014 | 0000000000 | |
| EP-3119763-A1 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Inactive | 18-Mar-2014 | 0000000000 | |
| US-20150266857-A1 | Novel 3-indol substituted derivatives, pharmaceutical compositions and methods for use | Inactive | 18-Mar-2014 | 0000000000 | |
| CA-2939164-A1 | Novel 3-(indol-3-yl)-pyridine derivatives, pharmaceutical compositions and methods for use | Inactive | 12-Feb-2014 | C07D401/04 |
iTeos Therapeutics Executive Team (16)
iTeos Therapeutics Board Members (24)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aaron Davis | Boxer Capital | Board Member | 000 0000 |
| Agustin Mohedas Ph.D | Janus Henderson Investors | Board Observer | 000 0000 |
| Ann Rhoads | Self | Board Member | 000 0000 |
| Benoît Eynde Ph.D | iTeos Therapeutics | Co-Founder & Chairman, Scientific Committee | 000 0000 |
| Bruno Montanari Ph.D | Self | Board Member | 000 0000 |
iTeos Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
iTeos Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
iTeos Therapeutics ESG
Risk Overview
Risk Rating
Updated December, 02, 2022
22.97 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.0
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 401
Rank
0.00
Percentile
